3d systems announces formation of new biotech company, systemic bio™, to accelerate drug discovery and development

Rock hill, s.c., sept. 08, 2022 (globe newswire) -- today, 3d systems (nyse:ddd) announced the formation of a new, wholly owned company called systemic bio ™, a biotech company focused on the application of advanced bioprinting technologies to pharmaceutical drug discovery and development. systemic bio will leverage 3d systems' breakthrough, production-level bioprinting technology to create extremely precise vascularized organ models using biomaterials and human cells. these proprietary organs-on-chips can be manufactured reproducibly in large quantities, and then perfused with any desired drug compound to study drug metabolism and the effects on healthy or diseased tissue at the earliest stages of new pharmaceutical drug development. the ability to accurately simulate human response to an experimental drug in the laboratory, early in the development process, offers the potential to significantly reduce both the high costs and extended times required for pharmaceutical companies to bring a new drug to market. in addition, this approach could eventually reduce or even eliminate the need for animal testing as a precursor to full-scale human trials for new drug development.
DDD Ratings Summary
DDD Quant Ranking